Healthcare - Biotechnology - NASDAQ - US
$ 0.00045
0 %
$ 8.54 K
Market Cap
0.0
P/E
CASH FLOW STATEMENT
-101 M
OPERATING CASH FLOW
-622 K
INVESTING CASH FLOW
81.7 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Evelo Biosciences, Inc.
| Net Income | -115 M |
| Depreciation & Amortization | 2.06 M |
| Capital Expenditures | -622 K |
| Stock-Based Compensation | 15.2 M |
| Change in Working Capital | -9.67 M |
| Others | -4.1 M |
| Free Cash Flow | -102 M |
Cash Flow
Millions
| Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (114.5) | (122.2) | (93.7) | (85.5) | (56.9) | (28.0) | (13.3) |
| Depreciation & Amortization | 2.1 | 2.2 | 2.0 | 1.8 | 1.9 | 0.8 | 0.5 |
| Deferred Income Tax | 0 | 3.2 | 6 K | (0.2) | 0.4 | 0.3 | 20 K |
| Stock Based Compensation | 15.2 | 15.8 | 8.5 | 8.2 | 6.1 | 1.5 | 0.4 |
| Other Operating Activities | 5.7 | 2.1 | 2.4 | 0.3 | 0.1 | 35 K | 28 K |
| Change in Working Capital | (9.7) | 2.1 | 7.8 | 3.5 | 1.2 | 2.1 | 56 K |
| Cash From Operations | (101.2) | (96.7) | (73.1) | (72.0) | (47.3) | (23.3) | (12.3) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (0.6) | (1.5) | (1.3) | (3.0) | (5.5) | (1.7) | (1.2) |
| Other Items | 0 | 38 K | 6 K | 55.0 | (54.7) | 0 | 10.5 |
| Cash From Investing Activities | (0.6) | (1.5) | (1.3) | 52.0 | (60.1) | (1.7) | 9.3 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 14.8 | 10.0 | 4.5 | 5.0 | 0 | 7.0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.9) | 1.0 | 0.5 | 0.5 | 81.2 | 49.0 | 8.7 |
| Cash From Financing Activities | 81.7 | 97.5 | 65.5 | 5.0 | 162.0 | 49.0 | 15.7 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (20.7) | (0.7) | (8.9) | (15.0) | 54.6 | 24.0 | 12.7 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (101.9) | (98.2) | (74.4) | (75.0) | (52.7) | (25.0) | (13.6) |